We plotted baseline levels of IGF-1 or IGFBP-3, and maximum percent tumor reduction, time to progression, maximum proportional changes in neutrophil or platelet counts, AUC of ganitumab, minimum observed concentration, Cmax, or t1/2, z (data not shown). This evidence concerns the gene IGF1 and neoplasm.